Elliot Israel, Juan Carlos Cardet, Jennifer K Carroll, Anne L Fuhlbrigge, Wilson D Pace, Nancy E Maher, Lilin She, Frank W Rockhold, Maureen Fagan, Victoria E Forth, Paulina Arias Hernandez, Brian K Manning, Jacqueline Rodriguez-Louis, Joel B Shields, Tamera Coyne-Beasley, Barbara M Kaplan, Cynthia S Rand, Wilfredo Morales-Cosme, Michael E Wechsler, Juan P Wisnivesky, Mary White, Barbara P Yawn, M Diane McKee, Paula J Busse, David C Kaelber, Sylvette Nazario, Michelle L Hernandez, Andrea J Apter, Ku-Lang Chang, Victor Pinto-Plata, Paul M Stranges, Laura P Hurley, Jennifer Trevor, Thomas B Casale, Geoffrey Chupp, Isaretta L Riley, Kartik Shenoy, Magdalena Pasarica, Rafael A Calderon-Candelario, Hazel Tapp, Ahmet Baydur
Asthma prevalence, morbidity, and mortality disproportionately impact African American/Black (AA/B) and Hispanic/Latinx (H/L) communities. Adherence to daily inhaled corticosteroid (ICS), recommended by asthma guidelines in all but the mildest cases of asthma, is generally poor. As-needed ICS has shown promise as a patient-empowering asthma management strategy, but it has not been rigorously studied in AA/B or H/L patients or in a real-world setting. Design and Aim The PeRson EmPowered Asthma RElief (PREPARE) Study is a randomized, open-label, pragmatic study which aims to assess whether a patient-guided, reliever-triggered ICS strategy called PARTICS (Patient-Activated Reliever-Triggered Inhaled CorticoSteroid) can improve asthma outcomes in AA/B and H/L adult patient populations...
December 11, 2020: Contemporary Clinical Trials